MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

The latest financial statement is for the quarter ending 2025-09-30.

Cash Flow Overview

Free Cash flow
-$20,513K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Consolidated net loss
-25,746 -34,413
Depreciation and amortization
165 333
Stock-based compensation
1,307 2,483
Accretion of discount of available-for-sale investment securities
512 981
Amortization of right-of-use assets
224 437
Other receivables
544 -1,238
Prepaid expenses and other assets
-4,795 -1,445
Accounts payable and accrued expenses
18 485
Operating lease liability
-183 -341
Net cash used in operating activities
-20,476 -29,314
Purchases of property and equipment
37 9
Purchases of available-for-sale investment securities
39,340 41,260
Maturities of available-for-sale investment securities
19,000 40,150
Net cash (used in) provided by investing activities
-20,377 -1,119
Proceeds from issuance of common stock through option exercises
0 19
Proceeds from issuance of common stock through employee stock purchase plan
0 79
Proceeds from issuance of common stock from at-the-market offerings, net of offering costs
29,753 36,691
Principal paid on finance lease liabilities
136 264
Net cash provided by financing activities
29,617 36,525
Net change in cash, cash equivalents and restricted cash
-11,236 6,092
Cash and cash equivalents at beginning of period
14,006 -
Cash and cash equivalents at end of period
8,862 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

aTYR PHARMA INC (ATYR)

aTYR PHARMA INC (ATYR)